scholarly journals Human Immunodeficiency Virus (HIV) Subtype Surveillance of African‐Born Persons at Risk for Group O and Group N HIV Infections in the United States

2000 ◽  
Vol 181 (2) ◽  
pp. 463-469 ◽  
Author(s):  
Patrick S. Sullivan ◽  
Ann N. Do ◽  
Dennis Ellenberger ◽  
Chou‐Pong Pau ◽  
Sindy Paul ◽  
...  
Author(s):  
Dawn K Smith ◽  
Patrick S Sullivan ◽  
Betsy Cadwell ◽  
Lance A Waller ◽  
Azfar Siddiqi ◽  
...  

Abstract Background Annual human immunodeficiency virus (HIV) diagnoses in the United States (US) have plateaued since 2013. We assessed whether there is an association between uptake of pre-exposure prophylaxis (PrEP) and decreases in HIV diagnoses. Methods We used 2012–2016 data from the US National HIV Surveillance System to estimate viral suppression (VS) and annual percentage change in diagnosis rate (EAPC) in 33 jurisdictions, and data from a national pharmacy database to estimate PrEP uptake. We used Poisson regression with random effects for state and year to estimate the association between PrEP coverage and EAPC: within jurisdictional quintiles grouped by changes in PrEP coverage, regressing EAPC on time; and among all jurisdictions, regressing EAPC on both time and jurisdictional changes in PrEP coverage with and without accounting for changes in VS. Results From 2012 to 2016, across the 10 states with the greatest increases in PrEP coverage, the EAPC decreased 4.0% (95% confidence interval [CI], −5.2% to −2.9%). On average, across the states and District of Columbia, EAPC for a given year decreased by 1.1% (95% CI, −1.77% to −.49%) for an increase in PrEP coverage of 1 per 100 persons with indications. When controlling for VS, the state-specific EAPC for a given year decreased by 1.3% (95% CI, −2.12% to −.57%) for an increase in PrEP coverage of 1 per 100 persons with indications. Conclusions We found statistically significant associations between jurisdictional increases in PrEP coverage and decreases in EAPC independent of changes in VS, which supports bringing PrEP use to scale in the US to accelerate reductions in HIV infections.


1991 ◽  
pp. 193-211
Author(s):  
Allison L. Greenspan ◽  
Ruth L. Berkelman ◽  
Timothy J. Dondero ◽  
James W. Curran

2020 ◽  
Vol 66 (2) ◽  
pp. S125
Author(s):  
Ashley Morgan Ebersole ◽  
Samantha J. Boch ◽  
Andrea E. Bonny ◽  
Deena J. Chisolm ◽  
Elise Berlan

Sign in / Sign up

Export Citation Format

Share Document